Cart
sales@molnova.com
J30-8
CAS No. 2366255-71-0
J30-8( —— )
Catalog No. M32969 CAS No. 2366255-71-0
J30-8 is a subtype-selective and potent JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity for the study of neurodegenerative diseases such as Alzheimer's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJ30-8
-
NoteResearch use only, not for human use.
-
Brief DescriptionJ30-8 is a subtype-selective and potent JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity for the study of neurodegenerative diseases such as Alzheimer's disease.
-
DescriptionJ30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetJNK
-
RecptorJNK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2366255-71-0
-
Formula Weight373.79
-
Molecular FormulaC17H9ClFN3O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 6.67 mg/mL (17.84 mM; Ultrasonic (<60°C)
-
SMILESFc1ccc2NC(=O)\C(=C3/S\C(NC3=O)=N/c3ccccc3Cl)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dou X, et al. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. J Med Chem. 2019 Jul 25;62(14):6645-6664.?
molnova catalog
related products
-
Tanzisertib
Tanzisertib (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1] and it blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis.
-
CC-401
CC-401 (JNK-401) is a potent, selective, ATP-competitive pan-JNK inhibitor with Ki of 25-50 nM.
-
JIP-1 (153-163)
Peptide inhibitor of c-Jun N-terminal kinase (JNK), based on residues 153-163 of JNK-interacting protein-1 (JIP-1). Binds to JNK with affinity in the micromolar range and minimally inhibits p38 and ERK.
